KYTHERA Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of prescription products for the aesthetic medicine market in the United States and internationally. Its product candidate ATX-101, is an injectable drug in late-stage clinical development for the the reduction of submental fat. The company also maintains research interest in hair and fat biology, pigmentation modulation, and facial contouring. It has a collaboration arrangement with Bayer Consumer Care AG and a related collaboration agreement with Bayer Consumer Care AG’s affiliate, Intendis GmbH to develop and commercialize ATX-101 outside the United St...
30930 Russell Ranch Road
Westlake Village, CA 91362
Founded in 2004
Kythera Biopharmaceuticals, Inc.(NasdaqGM:KYTH) dropped from NASDAQ Composite Index
Oct 4 15
Kythera Biopharmaceuticals, Inc. will be removed from Nasdaq Composite Index.
KYTHERA Biopharmaceuticals, Inc. Announces Board Changes
Oct 1 15
On October 1, 2015, in connection with the previously announced Amended and Restated Agreement and Plan of Merger, dated as of August 4, 2015, by and among KYTHERA Biopharmaceuticals, Inc., Allergan plc and Keto Merger Sub, Inc. In accordance with the terms of the Merger Agreement, each of Keith R. Leonard, Jr., Camille Samuels, Dennis Fenton, F. Michael Ball, Nathaniel David, Fran ois Kress, Hollings C. Renton, III and Joseph L. Turner resigned from his or her respective position as a member of KYTHERA's board of directors effective as of immediately prior to, and conditioned upon, the closing of the Merger. Upon the effectiveness of such resignations, the directors of Merger Sub as of immediately prior to the Effective Time (A. Robert D. Bailey and Maria Teresa Hilado) became the directors of the Surviving Corporation.
Kythera Biopharmaceuticals, Inc.(NasdaqGS:KYTH) dropped from NASDAQ Biotechnology Index
Sep 28 15
Kythera Biopharmaceuticals, Inc. will be removed from NASDAQ Biotech Index.